

COVID-19 vaccines – FDA makes recommendations for new monovalent vaccine composition for 2024-2025

- On June 13, 2024, the [FDA advised](#) that the preferred JN.1-lineage for the COVID-19 vaccines (2024 - 2025 formula) is the KP.2 strain, if feasible.
 - On June 5, 2024, the FDA's [Vaccine and Related Biological Products Advisory Committee \(VRBPAC\)](#) unanimously voted for the 2024 - 2025 formula of COVID-19 vaccines in the U.S. to include a monovalent JN.1-lineage.
- This change of recommending the KP.2 strain is intended to ensure that the COVID-19 vaccines (2024 - 2025 formula) more closely match circulating SARS-CoV-2 strains.
- Based on the [CDC's COVID Data Tracker](#), as of June 8, 2024, the KP.2 strain makes up 22.5% of COVID cases and the KP.3 strain makes up 25% of the cases.

What's Next?

- Vaccine manufacturers will submit their 2024 – 2025 formula COVID vaccines to the FDA for approval.
- The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) will meet on [June 27, 2024](#) to discuss and make recommendations on the FDA's approvals.
- The new vaccines are expected to be available in the August 2024 timeframe.